{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T10:35:47Z","timestamp":1752230147622},"reference-count":19,"publisher":"Akademiai Kiado Zrt.","issue":"11","license":[{"start":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T00:00:00Z","timestamp":1679184000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2023,3,19]]},"abstract":"<jats:p>M\u00e1r a 2000-es \u00e9vek elej\u00e9t\u0151l jelent\u0151sen javult a Hodgkin-lymphom\u00e1s betegek teljes\n                    \u00e9s betegs\u00e9gmentes t\u00fal\u00e9l\u00e9se, k\u00f6sz\u00f6nhet\u0151en az ABVD- (adriamicin, bleomicin,\n                    vinblasztin, dakarbazin) polikemoter\u00e1pia elterjed\u00e9s\u00e9nek \u00e9s a modern\n                    sug\u00e1rkezel\u00e9snek. Az ut\u00f3bbi \u00e9vekben tov\u00e1bbi diagnosztikus \u00e9s ter\u00e1pi\u00e1s\n                    v\u00e1ltoz\u00e1soknak lehett\u00fcnk tan\u00fai, melyek a betegek t\u00fal\u00e9l\u00e9s\u00e9t tov\u00e1bb jav\u00edtj\u00e1k. A\n                    legut\u00f3bbi \u00e9vtizedben \u00e9szlelt javul\u00e1sban jelent\u0151s szerepe van a diagnosztikai\n                    fejl\u0151d\u00e9snek, \u00edgy a ma m\u00e1r rutinszer\u0171en, a kezel\u00e9s sor\u00e1n ism\u00e9telten alkalmazott\n                        <jats:sup>18<\/jats:sup>FDG-PET\/CT vizsg\u00e1latnak, az ezen alapul\u00f3 v\u00e1laszadapt\u00e1lt\n                    kezel\u00e9s(ek)nek. Az ABVD-kezel\u00e9s uralkod\u00f3 szerepe az els\u0151 vonalbeli ter\u00e1pi\u00e1ban\n                    m\u00e9g mindig egy\u00e9rtelm\u0171, de nagyobb rizik\u00f3j\u00fa betegekn\u00e9l m\u00e1r c\u00e9lzott kezel\u00e9sk\u00e9nt az\n                    anti-CD30 monoklon\u00e1lis antitest (a brentuximab-vedotin) \u00e9s az AVD (adriamicin,\n                    vinblasztin, dakarbazin) kombin\u00e1ci\u00f3ja is el\u00e9rhet\u0151. A nagy rizik\u00f3j\u00fa,\n                    relab\u00e1l\u00f3\/refrakter betegek meggy\u00f3gy\u00edt\u00e1s\u00e1ban az autol\u00f3g haemopoeticus \u0151ssejtek\n                    transzplant\u00e1ci\u00f3j\u00e1nak szerepe v\u00e1ltozatlanul egy\u00e9rtelm\u0171, az ezt megel\u0151z\u0151 \u2019salvage\u2019\n                    kezel\u00e9sekben viszont m\u00e1r helye lehet\/van az \u00faj, c\u00e9lzott innovat\u00edv szereknek\n                    (brentuximab-vedotin, pembrolizumab) is. Az \u00faj ter\u00e1pi\u00e1s lehet\u0151s\u00e9gek \u00faj\n                    mell\u00e9khat\u00e1sokkal is j\u00e1rnak, amire e betegek ell\u00e1t\u00e1sa sor\u00e1n fel kell k\u00e9sz\u00fclni.\n                    \u00d6sszefoglal\u00f3nkban ezen \u00faj diagnosztikus \u00e9s ter\u00e1pi\u00e1s megk\u00f6zel\u00edt\u00e9seket mutatjuk\n                    be, saj\u00e1t gyakorlatunk \u00e9s tapasztalataink alapj\u00e1n. Orv Hetil. 2023; 164(11):\n                    403\u2013410.<\/jats:p>","DOI":"10.1556\/650.2023.32736","type":"journal-article","created":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T14:49:55Z","timestamp":1679237395000},"page":"403-410","update-policy":"http:\/\/dx.doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":2,"title":["Hodgkin-lymphom\u00e1s betegek kezel\u00e9s\u00e9vel szerzett tapasztalataink"],"prefix":"10.1556","volume":"164","author":[{"given":"\u00c1rp\u00e1d","family":"Ill\u00e9s","sequence":"first","affiliation":[{"name":"Debreceni Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati Int\u00e9zet, Hematol\u00f3giai Tansz\u00e9k Debrecen, Nagyerdei krt. 98., 4032 Magyarorsz\u00e1g"},{"name":"Debreceni Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Klinikai Orvostudom\u00e1nyok Doktori Iskola Debrecen Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ildik\u00f3","family":"Garai","sequence":"additional","affiliation":[{"name":"Scanomed Kft. Debrecen Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zs\u00f3fia","family":"Milt\u00e9nyi","sequence":"additional","affiliation":[{"name":"Debreceni Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati Int\u00e9zet, Hematol\u00f3giai Tansz\u00e9k Debrecen, Nagyerdei krt. 98., 4032 Magyarorsz\u00e1g"},{"name":"Debreceni Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Klinikai Orvostudom\u00e1nyok Doktori Iskola Debrecen Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1200\/JCO.2004.12.170","article-title":"ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results","volume":"22","author":"1 Bonadonna","year":"2004","unstructured":"1 Bonadonna G, Bonfante V, Viviani S, et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol. 2004; 22: 2835-2841.","journal-title":"J Clin Oncol"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1200\/JCO.2008.19.8820","article-title":"Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study","volume":"27","author":"2 Engert","year":"2009","unstructured":"2 Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009; 27: 4548-4554.","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3 Pincz\u00e9s L, Milt\u00e9nyi Zs, J\u00f3na \u00c1, et al. How the epidemiology of Hodgkin lymphoma changed in Debrecen, Hungary. Med Res Arch. 2016; 4: 6. ISSN 2375-1924. Available from: https:\/\/esmed.org\/MRA\/mra\/article\/view\/658 [accessed: 27 Jan, 2023].","DOI":"10.18103\/mra.v4i6.658"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"4 Cheson","year":"2014","unstructured":"4 Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32: 3059-3068.","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"5 Cheson","year":"2016","unstructured":"5 Cheson BD, Ansell S, Schwartz L, et al. Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 2016; 128: 2489-2496.","journal-title":"Blood"},{"key":"ref5","unstructured":"6 National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in oncology: Hodgkin lymphoma (version V.2. 2023). Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hodgkins.pdf [accessed: 27 Jan, 2023]."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"International Prognostic Factors Project on Advanced Hodgkin's Disease","volume":"339","author":"7 Hasenclever","year":"1998","unstructured":"7 Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998; 339: 1506-1514.","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"8 Andr\u00e9","year":"2017","unstructured":"8 Andr\u00e9 MP, Girinsky T, Federico M, et al. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial. J Clin Oncol. 2017; 35: 1786-1794.","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"9 Radford","year":"2015","unstructured":"9 Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med. 2015; 372: 1598-1607.","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group","volume":"37","author":"10 Fuchs","year":"2019","unstructured":"10 Fuchs M, Goergen H, Kobe C, et al. Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group. J Clin Oncol. 2019; 37: 2835-2845.","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"4504","DOI":"10.1182\/bloodadvances.2021005150","article-title":"Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial","volume":"5","author":"11 Ricardi","year":"2021","unstructured":"11 Ricardi U, Levis M, Evangelista A, et al. Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial. Blood Adv. 2021; 5: 4504-4514.","journal-title":"Blood Adv"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12 Connors JM, Jurczak W, Straus DJ, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma. N Engl J Med. 2018; 378: 331-344. Erratum: N Engl J Med. 2018; 378: 878.","DOI":"10.1056\/NEJMoa1708984"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/S1470-2045(13)70501-1","article-title":"Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study","volume":"14","author":"13 Younes","year":"2013","unstructured":"13 Younes A, Connors JM, Park SI, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013; 14: 1348-1356.","journal-title":"Lancet Oncol"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14 Cheson BD. Is BEACOPP better than ABVD? Curr Hematol Malig Rep. 2007; 2: 161-166.","DOI":"10.1007\/s11899-007-0022-2"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15 Yasenchak CA, Bordoni R, Patel-Donnelly D, et al. Frontline brentuximab vedotin as monotherapy or in combination for older Hodgkin lymphoma patients. J Clin Oncol. 2020; 38(15_Suppl): 8032.","DOI":"10.1200\/JCO.2020.38.15_suppl.8032"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1200\/JCO.21.01552","article-title":"Optimizing second-line therapy for Hodgkin lymphoma: a work in progress","volume":"39","author":"16 Bartlett","year":"2021","unstructured":"16 Bartlett NL. Optimizing second-line therapy for Hodgkin lymphoma: a work in progress. J Clin Oncol. 2021; 39: 3097-3103.","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"17 Younes","year":"2012","unstructured":"17 Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012; 30: 2183-2189.","journal-title":"J Clin Oncol"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18 Moln\u00e1r Zs, Pincz\u00e9s LI, Piukovics K, et al. Brentuximab vedotin treatment in patients with relapsed or refractory Hodgkin lymphoma. A Hungarian retrospective study. [Relab\u00e1l\u00f3\/refrakter Hodgkin-lymphoma brentuximab vedotin kezel\u00e9se. Hazai tapasztalatok.] Orv Hetil. 2017; 158: 1630-1634. [Hungarian]","DOI":"10.1556\/650.2017.30867"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1007\/s00277-020-04204-1","article-title":"Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma","volume":"99","author":"19 Pincz\u00e9s","year":"2020","unstructured":"19 Pincz\u00e9s LI, Szab\u00f3 R, Ill\u00e9s \u00c1, et al. Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma. Ann Hematol. 2020; 99: 2385-2392.","journal-title":"Ann Hematol"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/11\/article-p403.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/164\/11\/article-p403.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/164\/11\/article-p403.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T12:22:10Z","timestamp":1698150130000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/11\/article-p403.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,19]]},"references-count":19,"journal-issue":{"issue":"11"},"URL":"https:\/\/doi.org\/10.1556\/650.2023.32736","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,19]]}}}